Beam Therapeutics to Present Updated Clinical Data from BEACON Phase 1/2 Trial of Risto-cel in Sickle Cell Disease in an Oral Presentation at American Society of Hematology (ASH) Annual Meeting

What happened: Beam Therapeutics (Nasdaq: BEAM) will present updated BEACON Phase 1/2 data for risto-cel in sickle cell disease in an oral presentation at the ASH Annual Meeting, selected for ASH's official press program. Key numbers: ASH meeting December 12-15, 2026, in New Orleans; presentation December 12, 2026, 5:00-5:15 p.m. Why it matters: Beam says the data with more patients and longer follow-up continue to show a differentiated clinical and manufacturing profile, reinforcing confidence ahead of the anticipated BLA submission. Market: +2.3% today ($26.94), -0.7% YTD, 0.2x vol — as of 16:18 UTC

Beam Therapeutics (Nasdaq: BEAM) will present updated BEACON Phase 1/2 data for risto-cel in sickle cell disease in an oral presentation at the ASH Annual Meeting, selected for ASH's official press program.

Beam says the data with more patients and longer follow-up continue to show a differentiated clinical and manufacturing profile, reinforcing confidence ahead of the anticipated BLA submission. Market: +2.3% today ($26.94), -0.7% YTD, 0.2x vol — as of 16:18 UTC